Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked

Cell Cycle

Volumn 7, Issue 24, 2008, Pages 3898-3907

  Scrace, Simon F ^a   Kierstan, Peter ^a   Borgognoni, Jenifer ^a   Wang, Lan Zhen ^b   Denny, Sarah ^a   Wayne, Joanne ^a   Bentley, Carol ^a   Cansfield, Andrew D ^a   Jackson, Philip S ^a   Lockie, Andrea M ^a   Curtin, Nicola J ^b   Newell, David R ^b   Williamson, Douglas S ^a   Moore, Jonathan D ^a  

^a Vernalis PLC   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Apoptosis; BMS 387032; CDK inhibitors; Cyclins; DNA replication; Kinase; Mitosis; VER 54505

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PROTEIN MCL 1; PYRAZOLOPYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; VER 54505; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPLICATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MITOSIS;

EID: 58049221048     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.24.7345     Document Type: Article

References (50)

1. Nigg EA. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays 1995; 17:471-80.
2. Santamaría D, Barrière C, Cerqueira A, Hunt S, Tardy C, Newton K, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007; 448:811-5.
3. Moore JD, Kirk JA, Hunt T. Unmasking the S-phase-promoting potential of cyclin B1. Science 2003; 300:987-90.
4. Lolli G, Johnson LN. CAK-Cyclin-dependent activating kinase: a key kinase in cell cycle control and a target for drugs? Cell Cycle 2005; 4:572-7.
5. Peng J, Zhu Y, Milton JT, Price DH. Identification of multiple cyclin subunits of human P-TEFb. Genes Dev 1998; 12:755-62.
6. Sandhu C, Slingerland J. Deregulation of the cell cycle in cancer. Cancer Detect Prev 2000; 24:107-18.
7. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1:493-502.
8. Senderowicz AM. Inhibitors of cyclin-dependent kinase modulators for cancer therapy. Prog Drug Res 2005; 63:183-206.
9. Misra RN, Xiao HY, Kim KS, Lu S, Han WC, Barbosa SA, et al. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2- thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 2004; 47:1719-28.
10. Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 1999; 96:4325-9.
11. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003; 3:233-45.
12. Koumenis C, Giaccia A. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol Cell Biol 1997; 17:7306-16.
13. Sridhar J, Akula N, Pattabiraman N. Selectivity and potency of cyclin-dependent kinase inhibitors. AAPS J 2006; 8:204-21.
14. MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and downregulation of Mcl-1. Cancer Res 2005; 65:5399-407.
15. Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and downregulation of Mcl-1. Clin Cancer Res 2002; 8:3527-38.
16. Mohapatra S, Chu B, Zhao X, Pledger WJ. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res 2005; 65:7717-23.
17. Zhu Y, Alvarez C, Doll R, Kurata H, Schebye XM, Parry D, Lees E. S-phase checkpoint activation by direct CDK2 inhibition. Mol Cell Biol 2004; 24:6268-77.
18. Maude SL, Enders GH. Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response. Cancer Res 2005; 65:780-6.
19. Deans AJ, Khanna KK, McNees CJ, Mercurio C, Heierhorst J, McArthur GA. Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. Cancer Res 2006; 66:8219-26.
20. Cai D, Latham VM Jr, Zhang X, Shapiro GI. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006; 66:9270-80.
21. Cai D, Byth KF, Shapiro GI. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. Cancer Res 2006; 66:435-44.
22. 2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells. Mol Cell Biol 2001; 21:2755-66.
23. Williamson DS, Parratt MJ, Bower JF, Moore JD, Richardson CM, Dokurno P, et al. Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2. Bioorg Med Chem Lett 2005; 15:863-7.
24. 1/S cyclin-dependent kinases. J Biol Chem 1997; 272:12738-46.
25. Connell-Crowley L, Harper JW, Goodrich DW. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 1997; 8:287-301.
26. Byth KF, Geh C, Forder CL, Oakes SE, Thomas AP. The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor. Mol Cancer Ther 2006; 5:655-64.
27. Pascreau G, Arlot-Bonnemains Y, Prigent C. Phosphorylation of histone and histone-like proteins by aurora kinases during mitosis. Prog Cell Cycle Res 2003; 5:369-74.
28. Garriga J, Graña X. Cellular control of gene expression by T-type cyclin/CDK9 complexes. Gene 2004; 337:15-23.
29. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273:5858-68.
30. Pronk GJ, Ramer K, Amiri P, Williams LT. Requirement of an ICE-like protease for induction of apoptosis and ceramide generation by REAPER. Science 1996; 271:808-10.
31. Choong IC, Serafimova I, Fan J, Stockett D, Chan E, Cheeti S, et al. A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties. Bioorg Med Chem Lett 2008; doi:10.1016/j.bmcl.2008. 09.073
32. Zhou M, Halanski MA, Radonovich MF, Kashanchi F, Peng J, Price DH, Brady JN. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription. Mol Cell Biol 2000; 20:5077-86.
33. Larochelle S, Merrick KA, Terret ME, Wohlbold L, Barboza NM, Zhang C, et al. Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell 2007; 25:839-50.
34. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem 2000; 275:9390-5.
35. Lu W, Chen L, Peng Y, Chen J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 2001; 20:3206-16.
36. Carrassa L, Broggini M, Vikhanskaya F, Damia G. Characterization of the 5′flanking region of the human Chk1 gene: identification of E2F1 functional sites. Cell Cycle 2003; 2:604-9.
37. Vigo E, Müller H, Prosperini E, Hateboer G, Cartwright P, Moroni MC, Helin K. CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol Cell Biol 1999; 19:6379-95
38. Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci USA 1995; 92:12146-50.
39. Russo AJ, Magro PG, Hu Z, Li WW, Peters R, Mandola J, et al. E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. Cancer Res 2006; 66:7253-60.
40. Iavarone A, Massagué J. Repression of the CDK activator Cdc25A and cell cycle arrest by cytokine TGFbeta in cells lacking the CDK inhibitor p15. Nature 1997; 387:417-22.
41. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine downregulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96:393-7.
42. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109:399-404.
43. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, Lucas DM, Byrd JC. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: downregulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res 2007; 13:2144-50.
44. Parratt M, Bower JF, Williamson D, Cansfield A. Pyrazolopyrimidine compounds and their use in medicine. PCT Int Appl 2004; WO 2004087707.
45. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243:527-36.
46. Nekhai S, Shukla RR, Kumar A. A human primary T-lymphocyte-derived human immunodeficiency virus type 1 Tat-associated kinase phosphorylates the C-terminal domain of RNA polymerase II and induces CAK activity. J Virol 1997; 71:7436-41.
47. Caligiuri M, Becker F, Murthi K, et al. A proteome-wide CDK/CRK-specific kinase inhibitor promotes tumor cell death in the absence of cell cycle progression. Chem Biol 2005; 12:1103-11.
48. Wang S, Meades C, Wood G, Osnowski A, Anderson S, Yuill R, et al. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J Med Chem 2004; 47:1662-75.
49. Lane ME, Yu B, Rice A, Lipson KE, Liang C, Sun L, et al. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res 2001; 61:6170-7.
50. Davies TG, Bentley J, Arris CE, Boyle FT, Curtin NJ, Endicott JA, et al. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat Struc Biol 2002; 9:745-9.